Stockscreener 앱 받기
1.60
1.23%
-0.02
시간 외 거래:
1.60
전일 마감가:
$1.62
열려 있는:
$1.61
하루 거래량:
932.63K
Relative Volume:
3.86
시가총액:
$194.03M
수익:
-
순이익/손실:
$-19.57M
주가수익비율:
-0.5112
EPS:
-3.13
순현금흐름:
$-17.24M
1주 성능:
+9.59%
1개월 성능:
+4.58%
6개월 성능:
-17.53%
1년 성능:
-55.18%
1일 변동 폭
$1.515
$1.6699
1주일 범위
$1.44
$1.6699
52주 변동 폭
$1.33
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
(302) 295-3800
주소
1000 N. WEST STREET, SUITE 1200, WILMINGTON
IKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.60 | 196.45M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.96 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.42 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.17 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.67 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
While institutions invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) benefited from last week's 11% gain, individual investors stood to gain the most - simplywall.st
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Strong-Buy at Cantor Fitzgerald - MarketBeat
Contrasting Inhibikase Therapeutics (NASDAQ:IKT) & Liminatus Pharma (NASDAQ:LIMN) - Defense World
Inhibikase Therapeutics (IKT) Coverage Initiated by Cantor Fitzg - GuruFocus
Cantor Fitzgerald Initiates Coverage on Inhibikase Therapeutics (NYSE:IKT) - MarketBeat
Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the company - Yahoo Finance
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded at Zacks Research - MarketBeat
Is Inhibikase Therapeutics Inc. stock near bottom after decline2025 Earnings Surprises & Low Risk Entry Point Guides - Newser
Will Inhibikase Therapeutics Inc. (IQT0) stock beat value stocksPortfolio Risk Summary & Accurate Trade Setup Notifications - Newser
Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share - MSN
How big funds are accumulating Inhibikase Therapeutics Inc. (IQT0) stockWeekly Trade Report & Risk Controlled Swing Alerts - Newser
Will Inhibikase Therapeutics Inc. (IQT0) stock benefit from mergersPortfolio Risk Summary & Real-Time Volume Trigger Notifications - Newser
Inhibikase Therapeutics, Inc. (IKT) -5.96% in After-hours: Shares Drop Amid Ongoing Offerings - Stocks Telegraph
Why Inhibikase Therapeutics Inc. (IQT0) stock trades below fair valueDollar Strength & High Yield Equity Trading Tips - Newser
Will Inhibikase Therapeutics Inc. (IQT0) stock draw ESG focused fundsJuly 2025 Market Mood & Fast Exit Strategy with Risk Control - Newser
Will Inhibikase Therapeutics Inc. (IQT0) stock split increase liquidityWeekly Trade Report & Weekly Breakout Watchlists - Newser
FY2025 Earnings Estimate for IKT Issued By Lifesci Capital - MarketBeat
Can Inhibikase Therapeutics Inc. stock beat market expectations this quarterTrade Entry Summary & Real-Time Buy Zone Alerts - Newser
Will Inhibikase Therapeutics Inc. stock outperform tech sector in 20252025 Market Outlook & Capital Efficient Trade Techniques - Newser
Analysts Set Expectations for IKT FY2025 Earnings - Defense World
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to "Strong-Buy" at Lifesci Capital - MarketBeat
Is Inhibikase Therapeutics Inc. (IQT0) stock overpriced at current multiples2025 Market WrapUp & Fast Momentum Stock Entry Tips - Newser
Why Inhibikase Therapeutics Inc. (IQT0) stock fits value portfolios2025 Price Momentum & Weekly High Return Stock Forecasts - Newser
Inhibikase Therapeutics (NASDAQ:IKT) Raised to Strong-Buy at Lifesci Capital - Defense World
Inhibikase Therapeutics (IKT) Stock Analysis Report | Financials & Insights - Benzinga
How geopolitical tensions affect Inhibikase Therapeutics Inc. stockJuly 2025 News Drivers & Reliable Breakout Stock Forecasts - Newser
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress - MSN
Will Inhibikase Therapeutics Inc. stock recover faster than marketJuly 2025 WrapUp & Weekly Market Pulse Alerts - moha.gov.vn
Sands capital buys Inhibikase therapeutics (IKT) shares worth $3 million By Investing.com - Investing.com Australia
IKT Insider Trading - Quiver Quantitative
Sands capital buys Inhibikase therapeutics (IKT) shares worth $3 million - Investing.com
Owner Sands Capital Life Sciences Pulse Fund II LP Buys 2,068,965 ($3M) Of Inhibikase Therapeutics Inc [IKT] - TradingView
Sands Capital fund lifts IKT stake to 13.0M shares via $1.45 buy - Stock Titan
Inhibikase Therapeutics announces proposed public offering and pre-funded warrants - MSN
Inhibikase Therapeutics Announces $93.6 Million Stock Offering - MSN
Inhibikase Therapeutics Inc IQT0 Stock Analysis and ForecastGrowth Stock Opportunities & Interactive Learning for Better Returns - earlytimes.in
Four companies raise nearly $950M in follow-ons: Public Equity Report - BioCentury
[8-K] Inhibikase Therapeutics, Inc. Reports Material Event | IKT SEC FilingForm 8-K - Stock Titan
Inhibikase boosts cash runway with major PAH-focused equity raise - Stock Titan
Net current asset value per share of Inhibikase Therapeutics, Inc. – MUN:IQT0 - TradingView
Inhibikase Shares Climb After Revised Drug Timeline, Public Offering - marketscreener.com
Inhibikase Therapeutics Prices $100 Million Public Offering - MarketScreener
Inhibikase Therapeutics (IKT) Prices $100 Million Public Offerin - GuruFocus
Is Inhibikase Therapeutics Inc. stock a buy before product launchesJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Inhibikase Therapeutics, Inc. (IKT) Stock: Declines Amid $100 Million Public Offering Announcement - parameter.io
Inhibikase Therapeutics prices $100 million public offering - Investing.com India
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
1.90%
자본화:
|
볼륨(24시간):